2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

SESSION

621. Lymphomas: Translational – Molecular and Genetic

Program: Oral Abstract Session
Sunday, December 13, 2026
09:30 a.m. - 11:00 a.m.
MCCNO - 275-277
Technology and Procedures, Omics Technologies, Profiling, Biological Processes, Genomics, Molecular Biology, Multi-Systemic Interactions, Diseases, Lymphoid Malignancies, Lymphomas, Plasma Cell Disorders, Non-Hodgkin Lymphoma, B Cell Lymphoma, T Cell Lymphoma, Indolent Lymphoma, Aggressive Lymphoma, Research, Translational Research
PAPER

505 Enhancer remodeling hijacks a heb-ID2 regulatory circuit and exposes a therapeutic vulnerability in mature T-cell lymphoma

Anouchka P. Laurent, PhD, Ryan D. Najac2, Makoto Iwasaki, MD, PhD3, Eric Minwei Liu, PhD4, Hannah I. Miller5, Cindy Ma6, Robert Albero, PhD7, José Rodriguez Cortés, PhD8, Wen-Hsuan Wendy Lin, MD, PhD9, Ruth Alonso Alonso, PhD10, Laura Quevedo, PhD11, Anqi Wang, PhD12, Rajesh Soni, PhD13, Ouathek Ouerfelli, PhD14, Raul Rabadan, PhD15, Salvia Jain, MD16, Robert Benezra, PhD17, Teresa Palomero, PhD18
1 Columbia University, New York, New York, United States
2 Columbia University, New York, New York, United States
3 Massachusetts General Hospital, Boston, Massachusetts, United States
4 Massachusetts General Hospital Cancer Center, Boston, Massachusetts, United States, Massachusetts Institute of Technology, Cambridge, Massachusetts, United States
5 The Pershing Square Foundation, New York, New York, United States
6 Columbia University, New York, New York, United States
7 Universitat Autònoma de Barcelona, Barcelona, Spain
8 Regeneron Pharmaceuticals, Tarrytown, New York, United States
9 Duke University, Durham, North Carolina, United States
10 Auditorio Fundación MD Anderson Cancer Center España, Madrid, Spain
11 Columbia University, New York, New York, United States
12 Columbia University, New York, New York, United States
13 Columbia University, New York, New York, United States
14 Memorial Sloan Kettering Cancer Center, New York, New York, United States
15 Columbia University, New York, New York, United States
16 Massachusetts General Hospital, Boston, Massachusetts, United States
17 Memorial Sloan Kettering Cancer Center, New York, New York, United States
18 Columbia University, New York, New York, United States
Mature T-cell lymphomas (TCL) are a heterogeneous group of aggressive non-Hodgkin lymphomas characterized by poor overall survival with few available targeted therapies. Recurrent genomic alterations affecting epigenetic regulators across TCL implicate epigenetic dysregulation as a central driver of lymphomagenesis, while super enhancers (SE) are increasingly recognized as key oncogenic regulatory hubs in lymphoma. We previously identified aberrant activation of the inhibitor of DNA binding 2 (ID2) locus mediated by a TCL-associated SE, and established ID2 as a therapeutic vulnerability. ID2 is a well-characterized antagonist of E-protein transcription factors, but the elements and factors sustaining aberrant ID2 expression in TCL remain undefined. Here, we define this regulatory architecture controlling ID2 expression in TCL and evaluate an optimized pharmacologic strategy for ID2 inhibition.
 
To characterize the ID2 regulatory landscape in human TCL, we integrated chromatin conformation (Hi-C) and enhancer prediction analysis of 16 primary lymph-node biopsies from nodal peripheral T-cell lymphoma patients and 5 normal T-cells samples. In addition to a previously characterized proximal R1 SE, we identified a distal enhancer located 1.25Mb further upstream of the ID2 promoter. Using the high-confidence Peakachu algorithm loop probabilities (score ≥0.95), we observed that this distal regulatory element is significantly depleted in TCL, being detected in only 2/16 TCL samples versus 4/5 in normal T-cell samples (Fisher test, p=0.011). Consistent with these findings, Peakachu scores are significantly higher in normal T cells than in TCL (Mann-Whitney, p=0.0014). In contrast, the loop between the ID2 promoter and the R1 SE was detected by Peakachu in 12/16 TCL samples compared with 2/5 normal T-cell samples. Similarly, using H3K27ac CUT&RUN/TAG and ATAC-seq peaks with the Activity-By-Contact (ABC) model, we confirmed the loss of this distal enhancer in human TCL cell lines (n=6/7) and AITL and PTCL-NOS PDXs (n=2/3). Finally, chromatin profiling shows an enrichment of H3K27ac and H3K4me1 marks, and ATAC-seq peaks at this distal region in normal CD4+ T cells but not in murine TCL-derived cell lines (n=2/3). These findings indicate a consistent remodeling of ID2 enhancer activity during malignant transformation, marked by selective usage loss of the distal SE in favor of activation of the proximal R1 SE across models.
 
To identify the regulators sustaining the active R1 SE, we performed Reverse ChIP analysis and identified HEB, a basic helix-loop-helix transcription factor (TF) classically antagonized by ID2, as a shared TF candidate across models. Interestingly, across 20 human TCL cell lines from the Cancer Cell Line Encyclopedia, HEB expression strongly correlated with ID2 expression (r=0.809, p<0.0001). FIMO motif scanning confirmed the presence of multiple HEB binding sites within the R1 SE region while ChIP-qPCR validated HEB occupancy at the R1 SE in both human and murine TCL models. These data indicate that HEB sustains ID2 enhancer activity in TCL and identified the R1 SE as the site of its co-option in lymphomagenesis.
 
Finally, based on the promising anti-tumor activity previously observed with the first in class pan-ID inhibitor AGX51, we evaluated AGXA, a derivate with an improved solubility to support future clinical development. AGXA treatment reproducibly reduced cell number and increased apoptosis in both human and murine TCL models. In vitro at 72 hours, AGXA demonstrated IC50 values of 11.6 μM and 6.5 μM respectively in human and in murine TCL cell lines. AGXA also significantly reduced the proportion of cells in S phase in both models, consistent with impaired TCL proliferation. In vivo AGXA (40?mg/kg BID for 12 days) reduced tumor burden in our lymphoma murine model, with a significant decrease in spleen weight and tumor cell number relative to vehicle-treated controls.
 
In summary, our findings define a remodeled ID2 enhancer landscape in TCL, characterized by the loss of a distal regulatory element and preference for a HEB-bound proximal SE. We further establish AGXA as a soluble, potent small molecule inhibitor for ID2 inhibition. Together, these findings establish for the first time that TCL hijacks a conserved E-protein-ID circuit through disease-specific enhancer remodeling, establishing the HEB-ID2 regulatory axis as a therapeutically actionable vulnerability in mature T-cell lymphoma.
Anouchka P. Laurent, PhD: No relevant conflicts of interest to declare.